<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540368</url>
  </required_header>
  <id_info>
    <org_study_id>18-04-0393</org_study_id>
    <nct_id>NCT03540368</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for The Treatment of Gastrointestinal Bleeding</brief_title>
  <official_title>The Role of Tranexamic Acid for the Treatment of Gastrointestinal Bleeding: A Randomized Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies showed that in cases of gastrointestinal bleeding, injection tranexamic acid
      decreasing the risk of death and the need of surgical intervention. However, the quality of
      most clinical trials were not good and the results were not significant. Injection tranexamic
      acid does not become one of the treatment option in the international guidelines nor in
      national consensus, so the effectiveness and the safety of its use in the treatment of
      gastrointestinal bleeding remains unclear and not routinely used.

      In Indonesia, injection tranexamic acid in gastrointestinal bleeding is limitedly used and
      recorded. Therefore, a clinical trial study of injection tranexamic acid is required to
      assess the effectiveness and the safety in the treatment of gastrointestinal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized double-blind controlled trial study. Interventions were given in
      the form of tranexamic acid injection compared to placebo in patients with acute upper and
      lower gastrointestinal bleeding. Tranexamic acid were administered intravenously 1 gram
      loading dose, followed by 3 grams maintenance dose in infusion for 24 hours. Other routine
      and standardized drugs for gastrointestinal bleeding will still be given. Statistical
      analysis will use: Chi square test or Kolmogorov-Smirnov with alternative Fisher test for
      categorical dependent-variable; Independent T-Test with alternative Mann-Whitney test for
      two-group numerical dependent-variable; and one-way ANOVA with alternative Kruskal-Wallis for
      more than two-groups numerical dependent-variable.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>All patients will receive standard treatment equally</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Re-bleeding</measure>
    <time_frame>30 days after randomisation</time_frame>
    <description>Total incidence number of re-bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of death</measure>
    <time_frame>30 days after randomisation</time_frame>
    <description>Total number patients who die</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusion</measure>
    <time_frame>30 days after randomisation</time_frame>
    <description>Total number of patients with blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit</measure>
    <time_frame>30 days after randomisation</time_frame>
    <description>Average time of stay each participants in intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for endoscopic hemostasis</measure>
    <time_frame>30 days after randomisation</time_frame>
    <description>Total number of patients with endoscopic hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>30 days after randomisation</time_frame>
    <description>Short Form-36 Questionnaire includes one scale for each of eight measured health domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. All health domain scales are scored using norm-based scores ranging 0 to 100 with higher scores indicate better health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of anxiety</measure>
    <time_frame>30 days after randomisation</time_frame>
    <description>Hamilton Anxiety Rating Scale; Each item is scored of 0 (not present) to 4 (severe), with total score range of 0-56, where &lt;14 indicates no anxiety, 14-20 mild anxiety, 21-27 moderate anxiety, 28-41 severe anxiety and 42-56 very severe anxiety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group with tranexamic acid injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group with Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.</description>
    <arm_group_label>Tranexamic acid injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administering placebo or sodium chloride 0,9% intravenously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults

          -  Patients with acute lower and upper gastrointestinal bleeding (assessed clinically)

          -  Patients agreed to participate in the study and signed the informed consent

        Exclusion Criteria:

          -  Allergy with tranexamic acid

          -  Patients considered by the clinician can not be randomized to participate in the study

          -  Patients with chronic kidney disease stage III - V
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari F Syam, Dr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology Division, Internal Medicine Department RSCM/UI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ari F Syam, Dr, MD</last_name>
    <phone>+62818706199</phone>
    <email>ari_syam@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cipto Mangunkusumo National Central General Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari F Syam, Dr, MD</last_name>
      <phone>+6213153957</phone>
    </contact>
    <investigator>
      <last_name>Ari F Syam, Dr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murdani Abdullah, Prof, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcellus Simadibrata, Prof, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rabbinu R Pribadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Bennett C, Klingenberg SL, Langholz E, Gluud LL. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2014 Nov 21;(11):CD006640. doi: 10.1002/14651858.CD006640.pub3. Review.</citation>
    <PMID>25414987</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Ari Fahrial Syam</investigator_full_name>
    <investigator_title>Medical Doctor, Gastroenterology Hepatology Consultant</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal bleeding</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT03540368/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

